- Professor responsable de la Unitat de Medicina Bucal i dATM del Mster de Cirurgia Bucal i Implantologia Bucofacial de la Universitat de Barcelona (2016-2020)
Becejac et al., 2018
Start your intake How Semaglutide Changes Your Response to Sugar Semaglutide triggers satiety signals that make you feel full faster and keep you satisfied longer
Okifuji, A
Tirzepatides robust efficacy in reducing AHI, promoting weight loss, and improving cardiovascular and inflammatory markers heralds a new era in managing these interrelated conditions
Today is the Worst GLP1s+ Will Ever Be GLP1s+ More effective (5% to 22% weight loss and on their way to 25%+) More expansive disease management (diabetes, obesity, CVD, CKD, OSA, and studied for more) Less frequent (2x per day to 1x week and on their way to 1x/month to 1x/year?) Additional effective options in orals are on their way Insurance Coverage Medicare adding coverage for CVD (hopefully more diseases on the way as labels expand) Medicaid added 5 states in just 2023 Federal government added all employees and family members in 2023 Commercial employer coverage increased by 35% in 2023, with more employers considering it The Treat and Reduce Obesity Act (TROA) has been introduced in Congress to encourage Medicare coverage Costs Zepbound, a more effective drug, launched ~20-30% cheaper than Wegovy, with a savings card that put it at just over 1/3rd of the price at the time
